- FDA’s leadership void leaves biotech with renewed ‘uncertainty’<figure><div><img src="https://imgproxy.divecdn.com/FNb_NTnh8G1qxJJ4-eXNdCf1X5Oo0JaGYzOyuwyRsW4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjEzNTk5ODA2XzEua…BioPharma Dive · 2mo ago↗ source
- <![CDATA[Dr Bockorny on the Rationale for Targeting CCR8 in Solid Tumors ]]><![CDATA[Bruno B. Bockorny, MD, discusses the rationale for evaluating the anti-CCR8 antibody in a phase 1 trial in solid tumors. ]]>onclive · 2mo ago↗ source
- Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech,…